BB-K8 en es it fr

BB-K8 Brand names, BB-K8 Analogs

BB-K8 Brand Names Mixture

  • No information avaliable

BB-K8 Chemical_Formula


BB-K8 RX_link

BB-K8 fda sheet

BB-K8 msds (material safety sheet)


BB-K8 Synthesis Reference

H. Kawaguchi, T. Naito, Ger. pat. 2,234,315; H. Kawaguchi et al., U.S. pat. 3,781,268 (both 1973 to Bristol-Myers)

BB-K8 Molecular Weight

585.603 g/mol

BB-K8 Melting Point

203-204 oC

BB-K8 H2O Solubility

1.85E+005 mg/L

BB-K8 State


BB-K8 LogP


BB-K8 Dosage Forms

IM infusion; IM injection

BB-K8 Indication

For short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species.

BB-K8 Pharmacology

Amikacin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.

BB-K8 Absorption

Rapidly absorbed after intramuscular administration

BB-K8 side effects and Toxicity

No information avaliable

BB-K8 Patient Information

BB-K8 Organisms Affected

Enteric bacteria and other eubacteria